Skip to content
OpenCapital
Get started

ProShares UltraPro Short NASDAQ Biotechnology ZBIO Q4 2025 Annual earnings

Reported March 16, 2026 · Before market open

Diluted EPS-$1.10Miss by $0.10
Revenue estimate$13.3M
EPS estimate-$1.00

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$15.0M
EPS estimate-$0.89

Versus estimates

Revenue

Q1 2025$10.0MBeat by $8.8MQ4 2024$5.0M

Diluted EPS

Q1 2026-$1.46Beat by $0.01
Q4 2025-$1.10Miss by $0.10
Q3 2025-$1.22Miss by $0.35Q2 2025-$1.25Miss by $0.23Q1 2025-$0.80Beat by $0.31Q4 2024-$3.99Miss by $3.07

Ask the moment ProShares UltraPro Short NASDAQ Biotechnology reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did ProShares UltraPro Short NASDAQ Biotechnology report Q4 2025 earnings?
ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q4 2025 earnings on March 16, 2026 before market open.
What were ProShares UltraPro Short NASDAQ Biotechnology's Q4 2025 revenue and EPS?
ProShares UltraPro Short NASDAQ Biotechnology reported diluted EPS of $-1.10 for Q4 2025.
Did ProShares UltraPro Short NASDAQ Biotechnology beat estimates in Q4 2025?
EPS missed the consensus estimate of $-1.00 by $0.10.
How did ProShares UltraPro Short NASDAQ Biotechnology's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS grew 72.4% from $-3.99.
Where can I find ProShares UltraPro Short NASDAQ Biotechnology's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-027961) and the 10-K periodic report (0001104659-26-027964) directly on SEC EDGAR. The filing index links above go to sec.gov.